NCT00030849已完成2 期
Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 8
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
详细描述
OBJECTIVES:
- Determine the response rate and response duration in patients with cutaneous T-cell lymphoma when treated with bexarotene and, in the absence of a complete response, interferon alfa.
- Determine the safety and toxicity in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive oral bexarotene once daily for 8 weeks.
Patients with a complete response (CR) after 8 weeks continue bexarotene alone for at least another 8 weeks in the absence of unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast CancerBreast CancerNCT00004175Northwestern University
已完成
1 期
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00003993National Institute on Aging (NIA)24
已完成
2 期
Bryostatin 1 in Treating Patients With Stage IV Breast CancerBreast CancerNCT00003205University of Colorado, Denver
已完成
2 期
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney CancerKidney CancerNCT00039429Eastern Cooperative Oncology Group180
已完成
2 期
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00005847Eastern Cooperative Oncology Group